SPRINT®
PNS SYSTEM

SPRINT® Peripheral Nerve Stimulation (PNS) System Overview

The SPRINT Peripheral Nerve Stimulation (PNS) System is the only percutaneous PNS device FDA-cleared for both chronic and acute pain, including post-operative and post-traumatic pain. SPRINT is a minimally invasive and non-opioid neurostimulation device that is prescribed by a physician to deliver mild electrical pulses to a targeted peripheral nerve for a treatment period of up to 60 days. In studies, SPRINT has demonstrated significant and sustained pain relief in most patients.*

Components:

The SPRINT MicroLead™ The SPRINT MicroLead is constructed using very fine, coiled wire approximately twice the size of a human hair. It is implanted by the physician in an outpatient setting, typically under image-guidance, using a needle-based introducer. The MicroLead delivers mild electrical pulses targeted to a specific peripheral nerve.	
Pulse Generator The MicroLead is attached to an external pulse generator that is worn on the body.	
Remote The patient uses a small Bluetooth-enabled remote control to adjust the stimulation.	

How it works:
The SPRINT PNS System is uniquely designed to selectively and robustly stimulate targeted peripheral nerve fibers for up to 60 days, which is proposed to modulate central plasticity and enable significant and sustained pain relief.

The SPRINT System works by implanting a thin lead wire, the MicroLead™, typically under image-guidance, to target a peripheral nerve. The placement does not require surgery or incisions and is typically conducted as an outpatient procedure performed under local anesthesia. The MicroLead is connected to a wearable external generator that sends small electrical pulses to the nerve for up to 60 days. Patients can adjust the stimulation level as desired using a handheld Bluetooth-enabled remote control. After 60 days, the MicroLead is withdrawn in the physician's office.

Physicians have prescribed the SPRINT system to treat multiple pain conditions such as post-amputation pain, inoperable shoulder and knee joint pain, chronic low back pain, complex regional pain syndrome (CRPS), and post-operative pain following joint replacement and surgical reconstruction.
SPRINT is the most rigorously researched PNS system available with over 30 peer-reviewed publications. In multiple studies, the SPRINT PNS System has demonstrated significant and sustained improvements in pain and function in a majority of patients. Several post-market clinical trials are underway.

SPRINT PNS milestones

July 2016	SPRINT PNS is FDA-cleared, making it the first and only percutaneous PNS system FDA-cleared to treat both chronic and acute pain.
July 2018	SPRINT *endura*® and SPRINT *extensa*® are FDA-cleared allowing a single and a dual lead option, respectively. At the time of FDA-clearance, SPRINT *extensa*® was the only dual lead capable PNS platform.
October 2018	Department of Defense awards SPR Therapeutics $10M in grants and awards, bringing total to more than $30M from DoD and NIH, to support further clinical validation and advancement of SPR's neurostimulation technology for pain.
Dec 2019	The commercial placement of the 1,000th SPRINT PNS System.
June 2021	The commercial placement of the 5,000th SPRINT PNS System.
October 2021	SPR Therapeutics closes $37 million growth equity financing to be used to accelerate the rapidly growing commercial uptake, to fund additional clinical research, and to advance next generation technology.
October 2021	FDA clearance of an expanded Indication for the SPRINT PNS System device to be used in areas of the head, neck, and the front of the torso. The clearance was based on real world safety data collected from over 5,500 patients using the SPRINT PNS System commercially, both on-label and off-label.
May 2022	The commercial placement of the 10,000th SPRINT PNS System.

The SPRINT® Peripheral Nerve Stimulation (PNS) System is indicated for up to 60 days for: (i) symptomatic relief of chronic, intractable pain, post-surgical and post-traumatic acute pain; (ii) symptomatic relief of post-traumatic pain; (iii) symptomatic relief of post-operative pain. The SPRINT® PNS System is not intended to treat pain in the region innervated by the cranial and facial nerves.

Most common adverse events are skin irritation and erythema. Results may vary. Rx only.

For additional information regarding safety and efficacy, visit the SPR Therapeutics website.
 MKT-000026(02)

*References for Clinical Outcomes can be found on the SPR Therapeutics website.

Company Contact:
Michelle McDonald
Vice President – Marketing
mmcdonald@sprtherapeutics.com
844.378.9108

Media Contact:
Dave Folkens
Public Relations
Dfolkens@sprtherapeutics.com
612-978-6547

